Market power and state costs of HIV/AIDS drugs

@article{Leibowitz2007MarketPA,
  title={Market power and state costs of HIV/AIDS drugs},
  author={Arleen A. Leibowitz and Neeraj Sood},
  journal={International Journal of Health Care Finance and Economics},
  year={2007},
  volume={7},
  pages={59-71}
}
  • Arleen A. Leibowitz, Neeraj Sood
  • Published in
    International Journal of…
    2007
  • Economics, Medicine
  • We examine whether U.S. states can use their market power to reduce the costs of supplying prescription drugs to uninsured and underinsured persons with HIV through a public program, the AIDS Drug Assistance Program (ADAP). Among states that purchase drugs from manufacturers and distribute them directly to clients, those that purchase a greater volume pay lower average costs per prescription. Among states depending on retail pharmacies to distribute drugs and then claiming rebates from… CONTINUE READING

    Create an AI-powered research feed to stay up to date with new papers like this posted to ArXiv

    Figures, Tables, and Topics from this paper.

    Explore Further: Topics Discussed in This Paper

    References

    Publications referenced by this paper.
    SHOWING 1-10 OF 11 REFERENCES

    National ADAP Monitoring Project

    • J. Kates, M. Penner, B. Crutsinger-Perry, Leggoe, N. AW. Singleton
    • Annual Report 2005. Washington, D.C.: The Kaiser Family Foundation and National Alliance of State and Territorial AIDS Directors.
    • 2005
    VIEW 16 EXCERPTS
    HIGHLY INFLUENTIAL

    Prescription drug prices: why do some pay more than others do?

    VIEW 6 EXCERPTS
    HIGHLY INFLUENTIAL

    Agreements with Nine Companies Will Lower Prices of HIV Diagnosis and Two HIV/AIDS Medicines by 30–50 Percent for 50 Countries

    • Clinton Foundation.
    • Clinton Foundation Press Release dated January 12, 2006. New York, NY: Clinton Foundation. Available at www.clintonfoundation.org/011206nr-cf-hs-ai-isr-ind-chn-zaf. Accessed 24 March 2006.
    • 2006

    National ADAP Monitoring Project

    • J. Kates, Penner, M. Crutsinger-Perry, B. Carbaugh, N.A.L. Singleton
    • Annual Report 2006. Washington, D.C.: The Kaiser Family Foundation and National Alliance of State and Territorial AIDS Directors. Available at: www.kff.org/hivaids/upload/7464.pdf. Accessed March 30, 2006.
    • 2006

    National ADAP Monitoring Project

    • M. D. Davis, C. Aldridge, J. Kates, L. Chou
    • Annual Report. Washington, D.C.: The Kaiser Family Foundation and National Alliance of State and Territorial AIDS Directors
    • 2003

    Pharmaceuticals in U.S. health care: determinants of quantity and price.

    • Ernst R. Berndt
    • Economics, Medicine
    • The journal of economic perspectives : a journal of the American Economic Association
    • 2002
    VIEW 2 EXCERPTS

    Cost Containment of Medicaid HIV/AIDS Drug Expenditures

    • DHHS. Office of Inspector General.
    • Washington, D.C.: DHHS Office of Evaluation and Inspections. OEI-05–99–00611.
    • 2001

    HIV/AIDS Drugs: Funding Implications of New Combination Therapies for Federal and State Programs

    • U. S. Government Accountability Office.
    • Washington, D.C.: GAO/HEHS-99-2. 123
    • 1998